X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.980
-0.020 (-0.50%)
At close: Jul 31, 2026, 4:00 PM EDT
3.970
-0.010 (-0.25%)
After-hours: Jul 31, 2026, 7:34 PM EDT
X4 Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, X4 Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $11.6. The average 1-year stock price forecast is 191.46% higher than the current stock price, while the lowest is $10 (+151.26%) and the highest is $13 (+226.63%).
Price Target: $11.6 (+191.46%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for X4 Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Initiates $11 | Buy | Initiates | $11 | +176.38% | Jul 10, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $12 | Buy | Initiates | $12 | +201.51% | Jun 2, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $12 | Buy | Maintains | $12 | +201.51% | May 7, 2026 |
Financial Forecast
Revenue This Year
9.60M
from 35.11M
Decreased by -72.66%
Revenue Next Year
10.26M
from 9.60M
Increased by 6.88%
EPS This Year
-0.73
from -1.87
EPS Next Year
-0.82
from -0.73
EPS and Forward PE are based on non-GAAP adjusted numbers.